A Patient-Applied Therapy for the Treatment of External Genital and Perianal Warts
PLEASE SEE BELOW FOR IMPORTANT SAFETY INFORMATION
Important Safety Information
VEREGEN® (sinecatechins) has not been evaluated to treat urethral, intra-vaginal, cervical, rectal, or intra-anal human papilloma viral disease and should not be used to treat these conditions. Avoid use of VEREGEN® on open wounds.
Avoid exposure of VEREGEN®-treated areas to sun/UV-light because VEREGEN® has not been tested under these circumstances. Safety and efficacy of VEREGEN® have not been established in immunosuppressed patients or patients under 18 years of age, or pregnant women, or for the treatment of external genital and perianal warts beyond 16 weeks or for multiple treatment courses.
The most common adverse reactions are local skin and application site reactions including (incidence ≥ 20%) erythema, pruritus, burning, pain/discomfort, erosion/ulceration, edema, induration, and vesicular rash.
Please see link to full Prescribing Information.
(Click here for full Prescribing Information)
Veregen is a registered trademark of Medigene AG.
Veregen (sinecatechins) Dermcast TV is a program financially supported by PharmaDerm, a division of Fougera Pharmaceuticals Inc.
Ms. Block and Dr. Rosen are paid consultants of PharmaDerm.
©2017 Fougera Pharmaceuticals Inc. All rights reserved. P-VRG-1340359